US-based biotechnology firm Novavax has started enrolling participants in a Phase I/II clinical trial of its Covid-19 vaccine candidate, NVX‑CoV2373, in Australia.
Developed using the company’s nanoparticle technology, NVX‑CoV2373 is engineered from the genetic sequence of SARS‑CoV‑2.
The Phase I/II trial comprises two parts. The Phase I part is a randomised, observer-blinded, placebo-controlled study assessing the immunogenicity and safety of the vaccine candidate, adjuvanted with Matrix‑M, as well as unadjuvanted.
It is recruiting around 130 healthy participants aged 18 to 59 years at two sites in Australia.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData